We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Authors
Nierengarten, Mary Beth
- Abstract
"While there will still be a role for ibrutinib when it is used in combination with venetoclax or with chemoimmunotherapy in CLL and other lymphoid malignancies, I suspect that the use of ibrutinib will decrease overall in CLL/SLL based on these results." The final analysis of the phase 3 ALPINE trial shows that zanubrutinib confers superior progression-free survival (PFS) in comparison with ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). On January 19, 2023, the Food and Drug Administration approved zanubrutinib as a treatment for relapsed or refractory CLL/SLL on the basis of the ALPINE results and for untreated CLL/SLL on the basis of the SEQUOIA trial.[3] References 1 Brown JR, Eichhorst B, Hillman P, et al.
- Subjects
CHRONIC lymphocytic leukemia; LYMPHOCYTIC leukemia; LYMPHOMAS; BRUTON tyrosine kinase
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 10, p1466
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34811